55 research outputs found
Contact sensitization to essential oils: IVDK data of the years 2010â2019
Background: Essential oils (EOs) are widely used in cosmetics, perfumes, massage fluids, aroma therapy and natural medicine. Some EOs contain contact sensitizers.
Objectives: To describe the frequency of sensitization to EOs in dermatitis patients presenting in skin clinics including concomitant reactions, to evaluate the EO patch test preparations and to identify patient groups with an increased risk of EO sensitization.
Patients and methods: Retrospective analysis of data from the Information Network of Departments of Dermatology (IVDK), 2010-2019.
Results: Twelve EOs were patch tested in an aimed manner in 10 930 patients, of whom 908 (8.3%) reacted to at least 1 EO. Only 6 EOs elicited more than 1% positive patch test reactions: ylang ylang (I + II) oil (3.9%), lemongrass oil (2.6%), jasmine absolute (1.8%), sandalwood oil (1.8%), clove oil (1.6%) and neroli oil (1.1%). Concomitant reactions among EOs or to EOs and fragrances were frequent. Among EO-positive patients, women, leg dermatitis patients, patients aged 40 years or more, masseurs and cosmeticians were over-represented.
Conclusions: Sensitization to EOs occurs, albeit infrequently in most cases. Masseurs and cosmeticians have an increased risk of sensitization to EOs.
Keywords: clinical epidemiology; contact allergy; essential oils; fragrances; patch testin
Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial
Chronic spontaneous urticaria; On-demand; RupatadineUrticaria crónica espontånea; Bajo demanda; RupatadinaUrticà ria crònica espontà nia; Sota demanda; RupatadinaBackground
Non-sedating H1-antihistamines (nsAH) are the most commonly used treatment for chronic spontaneous urticaria (CSU). Many patients use them as on-demand (OD) therapy rather than a maintenance treatment. Here, we compared OD versus daily maintenance treatment with the nsAH rupatadine, assessed the efficacy of rupatadine updosing, and investigated potential long-term disease-modifying effects.
Methods
This multicenter, randomized study consisted of 2âweeks of screening, 8âweeks of double-blind treatment, and 6âweeks of treatment-free follow-up (OD allowed). Adult patients were randomized to 10âmg rupatadine OD or 10âmg rupatadine daily. At Week 4, if patients did not have a complete response, they switched from 10 to 20âmg rupatadine daily or underwent sham updosing (patients on 10âmg rupatadine OD). The primary aim was to compare CSU disease activity at the end of follow-up between daily versus OD. Additionally, we assessed the efficacy of rupatadine updosing. Major outcomes were disease activity, CSU-related quality of life (QoL), and disease control.
Results
At Week 4, disease activity and QoL significantly improved in daily versus OD-treated patients. Updosing of rupatadine did not improve the mean disease activity, but the number of complete responders increased during updosing from 5% to 22%. At the end of follow-up, the disease activity of patients treated OD versus daily was not significantly different.
Conclusions
Daily rupatadine treatment significantly improved CSU disease activity and QoL during treatment versus OD treatment but not after discontinuation of rupatadine, indicating the benefits of a daily maintenance nsAH schedule.This study was funded in part by URIACH, and the analysis was funded by CharitĂŠâUniversitätsmedizin Berlin as part of the âCU-LATERâ study. Other features of the study were supported by intramural funding. In addition, this study benefited from the network of Urticaria Centers of Reference and Excellence (UCAREs; https://ga2len-ucare.com) of GA2LEN, the Global Allergy and Asthma European Network
Contact sensitization to essential oils: IVDK data of the years 2010â2019
Abstract
Background
Essential oils (EOs) are widely used in cosmetics, perfumes, massage fluids, aroma therapy and natural medicine. Some EOs contain contact sensitizers.
Objectives
To describe the frequency of sensitization to EOs in dermatitis patients presenting in skin clinics including concomitant reactions, to evaluate the EO patch test preparations and to identify patient groups with an increased risk of EO sensitization.
Patients and methods
Retrospective analysis of data from the Information Network of Departments of Dermatology (IVDK), 2010â2019.
Results
Twelve EOs were patch tested in an aimed manner in 10â930 patients, of whom 908 (8.3%) reacted to at least 1 EO. Only 6 EOs elicited more than 1% positive patch test reactions: ylang ylang (Iâ+âII) oil (3.9%), lemongrass oil (2.6%), jasmine absolute (1.8%), sandalwood oil (1.8%), clove oil (1.6%) and neroli oil (1.1%). Concomitant reactions among EOs or to EOs and fragrances were frequent. Among EOâpositive patients, women, leg dermatitis patients, patients aged 40âyears or more, masseurs and cosmeticians were overârepresented.
Conclusions
Sensitization to EOs occurs, albeit infrequently in most cases. Masseurs and cosmeticians have an increased risk of sensitization to EOs
Impact of climate change on allergic diseases in Germany
Background: Allergic diseases, especially inhalant allergies, have reached epidemic levels and environmental factors play an important role in their development. Climate change influences the occurrence, frequency, and severity of allergic diseases.
Methods: The contents of this article were selected by the authors and developed section by section according to their expertise and the current state of knowledge. The sections were then discussed and agreed upon amongst all authors.
Results: The article highlights direct and indirect effects of climate change on allergies. It goes into detail about the connections between climate change and (new) pollen allergens as well as (new) occupational inhalation allergens, explains the effects of climate change on the clinical picture of atopic dermatitis, discusses the connections between air pollutants and allergies, and provides information about the phenomenon of thunderstorm asthma.
Conclusions: There is a need for action in the field of pollen and fungal spore monitoring, allergy and sensitisation monitoring, urban planning from an allergological perspective, and changes in the working environment, among others.
This is part of a series of articles that constitute the German Status Report on Climate Change and Health 2023
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcÎľRI-positive cells in the skin
Background. Treatment with omalizumab, a humanized recombinant monoclonal
anti-IgE antibody, results in clinical efficacy in patients with Chronic
Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has
not been elucidated in detail. Objectives. To determine the effects of
omalizumab on levels of high affinity IgE receptor-positive (FcÎľRI+) and IgE-
positive (IgE+) dermal cells and blood basophils. Treatment efficacy and
safety were also assessed. Study design. In a double-blind study, CSU patients
aged 18â75 years were randomized to receive 300 mg omalizumab (n=20) or
placebo (n=10) subcutaneously every 4 weeks for 12 weeks. Changes in disease
activity were assessed by use of the weekly Urticaria Activity Score (UAS7).
Circulating IgE levels, basophil numbers and levels of expression of FcÎľRI+
and IgE+ cells in the skin and in blood basophils were determined. Results.
Patients receiving omalizumab showed a significantly greater decrease in UAS7
compared with patients receiving placebo. At Week 12 the mean difference in
UAS7 between treatment groups was -14.82 (p=0.0027), consistent with previous
studies. Total IgE levels in serum were increased after omalizumab treatment
and remained elevated up to Week 12. Free IgE levels decreased after
omalizumab treatment. Mean levels of FcÎľRI+ skin cells in patients treated
with omalizumab 300 mg were decreased at Week 12 compared with baseline in the
dermis of both non-lesional and lesional skin, reaching levels comparable with
those seen in healthy volunteers (HVs). There were no statistically
significant changes in mean FcÉRI+ cell levels in the placebo group. Similar
results were seen for changes in IgE+ cells, although the changes were not
statistically significant. The level of peripheral blood basophils increased
immediately after treatment start and returned to Baseline values after the
follow-up period. The levels of FcÎľRI and IgE expression on peripheral blood
basophils were rapidly reduced by omalizumab treatment up to Week 12.
Conclusions. Treatment with omalizumab resulted in rapid clinical benefits in
patients with CSU. Treatment with omalizumab was associated with reduction in
FcÉRI+ and IgE+ basophils and intradermal cells
Auswirkungen des Klimawandels auf allergische Erkrankungen in Deutschland
Hintergrund: Allergische Erkrankungen, vor allem Inhalationsallergien, haben ein epidemisches Ausmaà erreicht, und Umweltfaktoren spielen eine wichtige Rolle bei ihrer Entstehung. Der Klimawandel beeinflusst Auftreten, Häufigkeit und Schwere allergischer Erkrankungen.
Methode: Die Inhalte dieses Artikels wurden durch die Autorinnen und Autoren ausgewählt und entsprechend ihren Expertisen nach dem aktuellen Wissensstand kapitelweise erarbeitet. Die Kapitel wurden anschlieĂend mit allen Autorinnen und Autoren diskutiert und abgestimmt.
Ergebnisse: Der Artikel beleuchtet direkte und indirekte Effekte des Klimawandels auf Allergien. Er geht näher auf Zusammenhänge zwischen Klimawandel und (neuen) Pollenallergenen sowie (neuen) beruflichen Inhalationsallergenen ein, erläutert Auswirkungen des Klimawandels auf das Krankheitsbild der Neurodermitis, geht auf Zusammenhänge zwischen Luftschadstoffen und Allergien ein und informiert ßber das Phänomen des Gewitterasthmas.
Schlussfolgerungen: Es besteht unter anderem Handlungsbedarf fßr die Bereiche Pollen- und Schimmelpilzsporenmonitoring, Allergie- und Sensibilisierungsmonitoring, Städteplanung unter allergologischen Gesichtspunkten und Veränderungen der Arbeitswelt.
Dieser Artikel ist Teil der Beitragsreihe zum Sachstandsbericht Klimawandel und Gesundheit 2023
AÂ position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ĂGAI
Background: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral sequence, these vaccines were approved for use in the European Union (EU) as well as in numerous other countries and mass vaccination efforts began. The so far in the EU approved mRNA vaccines BNT162b2 and mRNA-1273 are based on similar lipid-based nanoparticle carrier technologies; however, the lipid components differ. Severe allergic reactions and anaphylaxis after COVID-19 vaccination are very rare adverse events but have drawn attention due to potentially lethal outcomes and have triggered a high degree of uncertainty.
Methods: Current knowledge on anaphylactic reactions to vaccines and specifically the new mRNA COVID-19 vaccines was compiled using a literature search in Medline, PubMed, as well as the national and international study and guideline registries, the Cochrane Library, and the Internet, with special reference to official websites of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), Robert Koch Institute (RKI), and Paul Ehrlich Institute (PEI).
Results: Based on the international literature and previous experience, recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts.
Conclusion: Allergy testing is not necessary for the vast majority of allergic patients prior to COVID-19 vaccination with currently licensed vaccines. In case of allergic/anaphylactic reactions after vaccination, allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Evaluation and approval of diagnostic tests should be done for this purpose
Healthcare provision for insect venom allergy patients during the COVID-19 pandemic
The population prevalence of insect venom allergy ranges between 3â5%, and it can lead to potentially life-threatening allergic reactions. Patients who have experienced a systemic allergic reaction following an insect sting should be referred to an allergy specialist for diagnosis and treatment. Due to the widespread reduction in outpatient and inpatient care capacities in recent months as a result of the COVID-19 pandemic, the various allergy specialized centers in Germany, Austria, and Switzerland have taken different measures to ensure that patients with insect venom allergy will continue to receive optimal allergy care. A recent data analysis from the various centers revealed that there has been a major reduction in newly initiated insect venom immunotherapy (a 48.5% decline from MarchâJune 2019 compared to MarchâJune 2020: data from various centers in Germany, Austria, and Switzerland). The present article proposes defined organizational measures (e.g., telephone and video appointments, rearranging waiting areas and implementing hygiene measures and social distancing rules at stable patient numbers) and medical measures (collaboration with practice-based physicians with regard to primary diagnostics, rapid COVID-19 testing, continuing already-initiated insect venom immunotherapy in the outpatient setting by making use of the maximal permitted injection intervals, prompt initiation of insect venom immunotherapy during the summer season, and, where necessary, using outpatient regimens particularly out of season) for the care of insect venom allergy patients during the COVID-19 pandemic
Ligelizumab for Chronic Spontaneous Urticaria
Background: In the majority of patients with chronic spontaneous urticaria, most currently available therapies do not result in complete symptom control. Ligelizumab is a next-generation high-affinity humanized monoclonal anti-IgE antibody. Data are limited regarding the doseâresponse relationship of ligelizumab and the efficacy and safety of ligelizumab as compared with omalizumab and placebo in patients who have moderate-to-severe chronic spontaneous urticaria that is inadequately controlled with H1-antihistamines at approved or increased doses, alone or in combination with H2-antihistamines or leukotriene-receptor antagonists.
Methods: In a phase 2b dose-finding trial, we randomly assigned patients to receive ligelizumab at a dose of 24 mg, 72 mg, or 240 mg, omalizumab at a dose of 300 mg, or placebo, administered subcutaneously every 4 weeks for a period of 20 weeks, or a single 120-mg dose of ligelizumab. Disease symptoms of hives, itch, and angioedema were monitored by means of weekly activity scores. The main objective was to determine a doseâresponse relationship for the complete control of hives (indicated by a weekly hives-severity score of 0, on a scale from 0 to 21, with higher scores indicating greater severity); the primary end point of this response was assessed at week 12. Complete symptom control was indicated by a weekly urticaria activity score of 0 (on a scale from 0 to 42, with higher scores indicating greater severity). Safety was analyzed throughout the trial.
Results: A total of 382 patients underwent randomization. At week 12, a total of 30%, 51%, and 42% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete control of hives, as compared with 26% of the patients in the omalizumab group and no patients in the placebo group. A doseâresponse relationship was established. At week 12, a total of 30%, 44%, and 40% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete control of symptoms, as compared with 26% of the patients in the omalizumab group and no patients in the placebo group. In this small and short trial, no safety concerns regarding ligelizumab or omalizumab emerged.
Conclusions: A higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelizumab therapy of 72 mg or 240 mg than with omalizumab or placebo. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT02477332. opens in new tab.
Reduction of Cross-Reactive Carbohydrate Determinants in Plant Foodstuff: Elucidation of Clinical Relevance and Implications for Allergy Diagnosis
Background: A longstanding debate in allergy is whether or not specific immunoglobulin-E antibodies (sIgE), recognizing cross-reactive carbohydrate determinants (CCD), are able to elicit clinical symptoms. In pollen and food allergy, $20% of patients display in-vitro CCD reactivity based on presence of a1,3-fucose and/or b1,2-xylose residues on N-glycans of plant (xylose/fucose) and insect (fucose) glycoproteins. Because the allergenicity of tomato glycoallergen Lyc e 2 was ascribed to N-glycan chains alone, this study aimed at evaluating clinical relevance of CCD-reduced foodstuff in patients with carbohydrate-specific IgE (CCD-sIgE).
Methodology/Principal Findings: Tomato and/or potato plants with stable reduction of Lyc e 2 (tomato) or CCD formation in general were obtained via RNA interference, and gene-silencing was confirmed by immunoblot analyses. Two different CCD-positive patient groups were compared: one with tomato and/or potato food allergy and another with hymenopteravenom allergy (the latter to distinguish between CCD- and peptide-specific reactions in the food-allergic group). Nonallergic and CCD-negative food-allergic patients served as controls for immunoblot, basophil activation, and ImmunoCAP analyses. Basophil activation tests (BAT) revealed that Lyc e 2 is no key player among other tomato (glyco)allergens. CCDpositive patients showed decreased (re)activity with CCD-reduced foodstuff, most obvious in the hymenoptera venomallergic but less in the food-allergic group, suggesting that in-vivo reactivity is primarily based on peptide- and not CCDsIgE. Peptide epitopes remained unaffected in CCD-reduced plants, because CCD-negative patient sera showed reactivity similar to wild-type. In-house-made ImmunoCAPs, applied to investigate feasibility in routine diagnosis, confirmed BAT results at the sIgE level.
Conclusions/Significance: CCD-positive hymenoptera venom-allergic patients (control group) showed basophil activation despite no allergic symptoms towards tomato and potato. Therefore, this proof-of-principle study demonstrates feasibility of CCD-reduced foodstuff to minimize âfalse-positive resultsâ in routine serum tests. Despite confirming low clinical relevance of CCD antibodies, we identified one patient with ambiguous in-vitro results, indicating need for further component-resolved diagnosis
- âŚ